<DOC>
	<DOCNO>NCT00936936</DOCNO>
	<brief_summary>The goal clinical research study learn 2 cycle high-dose chemotherapy help control germ-cell tumor . The first cycle chemotherapy include drug gemcitabine , docetaxel , melphalan , carboplatin . The second cycle chemotherapy include drug ifosfamide , carboplatin , etoposide . The safety drug combination also study .</brief_summary>
	<brief_title>High-dose Chemotherapy Poor-Prognosis Relapsed Germ-Cell Tumors</brief_title>
	<detailed_description>The Study Drugs : Carboplatin , melphalan , ifosfamide design damage DNA ( genetic material ) cancer cell , may cause cancer cell die . Docetaxel etoposide design stop growth cancer cell , may cause cancer cell die . Gemcitabine design disrupt growth cancer cell , may cause cancer cell die . It may also help docetaxel , carboplatin , melphalan effective stop tumor cell repair damage cause drug . Study Drug Administration : You receive 2 cycle high-dose chemotherapy stem-cell support , 1-2 month apart . Starting first day hospital stay , begin gargle swish Caphosol Glutamine mouth 4 time day . This do help prevent mouth throat sore . On Day 2 stay hospital , CVC , receive gemcitabine 4 hour docetaxel 2 hour . On Days 3-5 , CVC , receive gemcitabine 4 hour , melphalan 15 minute , carboplatin 2 hour . On Day 6 , receive study drug . On Day 7 , receive stem cell CVC 30-60 minute . As part standard care , receive G-CSF ( filgrastim ) injection skin daily , start 5 day transplant , blood cell level return normal . As part standard mouth care ask mouthwash 4 time day caphosol ( artificial saliva ) glutamine . Two ( 2 ) 4 week leave hospital Cycle 1 , receive second cycle high-dose chemotherapy . On Days 2-4 stay hospital , CVC , receive ifosfamide 6 hour , etoposide 2 hour , carboplatin 2 hour . On Days 5-6 , receive study drug . On Day 7 , receive stem cell CVC 30-60 minute . Study Visits : About 1 month , 100 day , 6 month 1 year second stem cell transplant , follow test procedure perform : - To check status disease , CT scan chest , abdomen , pelvis . - Blood ( 3 tablespoon ) draw routine test . Length Study : You study 1 year second transplant . You take study early disease get bad experience intolerable side effect . Long-Term Follow-up : If doctor think need , may follow-up visit . Additional Information : As part routine care , remain hospital 3-4 week stem cell transplant . After release hospital , must remain Houston area monitor infection transplant-related complication . This investigational study . Gemcitabine , docetaxel , melphalan , ifosfamide , carboplatin , etoposide FDA-approved commercially available treatment germ-cell tumor . Up 67 patient enrol study .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>1 . Male female patient , age 12 65 year . 2 . Patients seminomatous nonseminomatous germcell tumor ( GCT ) one follow group : A ) First relapse progression second response intermediate high risk accord Beyer model . B ) Second relapse beyond . 3 . Adequate renal glomerular tubular function , define estimate serum creatinine clearance &gt; /=50 ml/min and/or serum creatinine &lt; /= 1.8 mg/dL , urinary protein excretion &lt; /=500 mg/day . 4 . Adequate hepatic function , define ALT AST &lt; /=3 x upper limit normal ( ULN ) ; serum bilirubin alkaline phosphatase &lt; /=2 x ULN consider clinically significant . 5 . Adequate pulmonary function FEV1 ( Forced expiratory volume first second ) , FVC ( Forced vital capacity ) DLCO ( diffuse capacity lung carbon monoxide ) &gt; /=50 % predict , correct volume hemoglobin . 6 . Adequate cardiac function LVEF ( leave ventricular ejection fraction ) &gt; /=40 % . No uncontrolled arrhythmias symptomatic cardiac disease . 7 . Zubrod performance status 02 . 8 . A minimum apheresis collection 5 million CD34+ cells/kg autologous hematopoietic progenitor cell ( AHPC ) . 9 . Written informed consent patient and/ parent legal guardian . Assent patient inclusive age 12 17 . 1 . Growing teratoma syndrome , define enlarge tumor mass normal serum marker chemotherapy nonseminomatous GCT . 2 . Major surgery within 30 day initiation study treatment 3 . Radiotherapy within 21 day prior initiation study treatment 4 . Prior whole brain irradiation . 5 . Patients active central nervous system ( CNS ) disease , define brain meningeal metastases complete remission . 6 . Patients active hepatitis B , either active carrier ( HBsAg + ) viremic ( HBV DNA &gt; /=10,000 copies/mL , &gt; /= 2,000 IU/mL ) . 7 . Evidence either cirrhosis stage 34 liver fibrosis patient either show chronic hepatitis C positive hepatitis C serology . 8 . Active infection require parenteral antibiotic . 9 . HIV infection , unless patient receive effective antiretroviral therapy undetectable viral load normal CD4 count 10 . Patients previous autologous allogeneic stem cell transplant previous 12 month . 11 . Positive pregnancy test female patient childbearing potential define post menopausal twelve month previous surgical sterilization .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Testis</keyword>
	<keyword>Relapsed Testicular Cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Etoposide</keyword>
	<keyword>VePesid</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Ifosfamide</keyword>
	<keyword>Ifex</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
</DOC>